Innate Pharma (IPHA) Interest Expenses (2019 - 2025)

Innate Pharma (IPHA) has 7 years of Interest Expenses data on file, last reported at -$3.6 million in Q4 2025.

• For the quarter ending Q4 2025, Interest Expenses rose 14.5% year-over-year to -$3.6 million; the trailing twelve-month figure through Dec 2025 stood at -$13.3 million (down 39.79% YoY), and the FY2025 full-year result was $3.6 million, down 14.5% from the prior year.
• Interest Expenses for Q4 2025 stood at -$3.6 million, down from -$3.2 million in the prior quarter.
• Across five years, Interest Expenses topped out at -$5428.7 in Q4 2022 and bottomed at -$6.6 million in Q2 2022.
• The 5-year median for Interest Expenses is -$3.2 million (2025), against an average of -$3.1 million.
• The widest annual swing landed in 2022, when Interest Expenses jumped 99.88%; it then tumbled 36268.5% in 2023.
• A 5-year view of Interest Expenses shows it stood at -$4.6 million in 2021, then surged by 99.88% to -$5428.7 in 2022, then sank by 36268.5% to -$2.0 million in 2023, then slumped by 115.14% to -$4.2 million in 2024, then gained by 14.5% to -$3.6 million in 2025.
• The last three Interest Expenses figures came in at -$3.6 million (Q4 2025), -$3.2 million (Q2 2025), and -$4.2 million (Q4 2024), per Business Quant data.

Peer Comparison